Stoke Therapeutics Inc represents values of innovation, collaboration, and commitment to patients. The company's corporate philosophy revolves around developing transformative treatments for severe genetic diseases. Stoke is dedicated to harnessing the power of RNA biology to address the underlying cause of such diseases. By prioritizing scientific advancement and partnerships, Stoke Therapeutics Inc aims to make a positive impact on patients' lives. The company strives to excel in translating cutting-edge research into therapeutic breakthroughs, offering hope and delivering long-term value for patients, their families, and the healthcare community.

Stoke Therapeutics Inc is primarily present in the United States.

Stoke Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering in June 2019, raising approximately $142 million in net proceeds. In January 2020, Stoke Therapeutics received the FDA's rare pediatric disease designation for its lead product candidate, STK-001, which aims to treat Dravet syndrome, a severe form of epilepsy. Furthermore, the company initiated a Phase 1/2a clinical trial of STK-001 in October 2020. Stoke Therapeutics continues to make progress in advancing its pipeline and developing innovative therapies for genetic diseases.

Stoke Therapeutics Inc is a biotechnology company founded in 2018, based in Bedford, Massachusetts. Focused on addressing the underlying causes of severe genetic diseases, Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform enables the development of antisense oligonucleotide (ASO) therapies to increase protein levels and restore gene expression. By targeting RNA instead of DNA, Stoke Therapeutics aims to treat a range of genetic disorders, including genetic epilepsies, genetic conditions affecting the central nervous system, and other rare diseases. Their innovative approach holds promise for patients with limited treatment options, making Stoke Therapeutics a key player in the biotech industry.

The main competitors of Stoke Therapeutics Inc in the market include companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.

Stoke Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Stoke Therapeutics Inc revolves around developing innovative RNA-targeted therapeutics to treat severe genetic diseases. By focusing on addressing the underlying causes of diseases, Stoke Therapeutics aims to provide long-term solutions for patients. Its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), enables the modulation of gene expression levels to restore the production of functional proteins. Stoke Therapeutics collaborates with industry partners and utilizes its expertise in RNA biology to advance potential therapies for a range of genetic disorders. Through its business model, the company aims to improve the lives of patients with severe genetic diseases through innovative and targeted treatments.

Stoke Therapeutics KGV ir -5,66.

Stoke Therapeutics KUV ir 41,37.

AlleAktien kvalitātes vērtējums Stoke Therapeutics ir 3/10.

gaidāmā Stoke Therapeutics apgrozījums ir 15,63 milj. USD.

gaidāmā Stoke Therapeutics peļņa ir -114,30 milj. USD.

Stoke Therapeutics Inc. is a biopharmaceutical company focused on developing technologies and therapies for the treatment of rare genetic diseases. Their business model is based on the application of a novel technology platform called Targeted Augmentation of Nuclear Gene Output (TANGO), which allows for the increase or decrease of gene expression. They aim to achieve therapeutic effects by specifically augmenting gene expression through their TANGO platform, which involves developing RNA molecules known as antisense oligonucleotides (ASOs) to modulate gene expression. Stoke Therapeutics has multiple products in various stages of development, with their most advanced candidate, STK-001, targeting the treatment of autosomal recessive spinobulbar muscular atrophy (SMA). They are also working on therapies for other rare diseases such as autosomal dominant optic atrophy (ADOA) and Dravet syndrome. Overall, Stoke Therapeutics focuses on developing RNA-based therapeutics for rare genetic diseases caused by loss-of-function mutations.

Stoke Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Stoke Therapeutics vai uzņēmums nedod dividendes.

Stoke Therapeutics ISIN ir US86150R1077.

Stoke Therapeutics WKN ir A2PLTL.

Stoke Therapeutics simbols ir STOK.

Pēdējo 12 mēnešu laikā Stoke Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Stoke Therapeutics plāno maksāt dividendes 0 USD apmērā.

Stoke Therapeutics pašreizējā dividendu rentabilitāte ir .

Stoke Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Stoke Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Stoke Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Stoke Therapeutics apmērā 0 USD, kas tika izmaksāta 9.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.09.2024..

Pēdējās dividendes izmaksa notika 9.09.2024..

Gadā 2023, Stoke Therapeutics izmaksāja 0 USD dividendes.

Stoke Therapeutics dividendes tiek izmaksātas USD.